Abstract In the USA, increasing attention is being paid to adopting a value-based framework for measuring and ultimately improving health care delivery. Value is defined as the benefit achieved relative to costs. The numerator of the value equation includes quality of care and outcomes achieved. The denominator includes costs, both financial costs and harms of treatment. Herein, we describe these elements of value as they pertain to head and neck cancer. A particular focus is to identify areas of the value equation where physicians have some control. We examine quality in each of three dimensions: structure, process, and outcomes. We also adopt Porter's three-tiered hierarchy of outcomes model, with specific outcomes relevant to patients with head and neck and thyroid cancer. Finally, we review issues related to costs and harms. We believe these findings can serve as a framework for further efforts to drive value-based delivery of head and neck cancer care.
Introduction
Value in health care, as with any product, is defined as the benefit of the thing being purchased, divided by the cost of purchasing it [1••] . In the US health care system, increasing attention is being paid to the numerator: the benefits, including outcomes and quality of care. Efforts such as those embodied by the Patient-Centered Outcomes Research Institute (PCORI) point to the growing importance of making sure the benefits we get from health care are ones that really matter to patients, the consumers of health care [2] . Increasing attention is also being paid to the denominator-the costs of health care, which includes not only financial costs but also potential harms. Recent Institute of Medicine (IOM) reports on US health care costs highlight the issues of cost growth and waste and provide a framework for needed change [3, 4] . The categories of waste in health care (Table 1) have received heightened attention through media publicity and efforts such as the Choosing Wisely campaign [5, 6••] .
In cancer care as compared to other fields of medicine, addressing the numerator and denominator of the value equation has its own unique challenges, driven in part by increasingly chronic care for an aging population of cancer survivors, the high cost of new cancer diagnostic and therapeutic technologies, and disparities in access to highquality care. In 2013, the IOM published findings from a workshop and formal report on these challenges in cancer care [7, 8••] . In head and neck cancer in particular, these challenges may be further amplified by the unique multidisciplinary care required for achieving good outcomes, the importance of functional rehabilitation after treatment, and the rapidly changing landscape of disease etiology (e.g., human papillomavirus) and technology (e.g., robotic surgery).
In this article, we will describe the elements of the numerator and denominator of the value equation and review each of them in the context of head and neck cancer. These findings can serve as a framework for further efforts to drive valuebased delivery of head and neck cancer care. Figure 1 describes the elements of the value equation. Value is increased when the numerator is improved, when the denominator shrinks, or both. It should be noted that very expensive health care interventions may be high value as long as the benefit is large. Conversely, inexpensive interventions may be low value if they provide little benefit or more harm than good.
Defining the Elements of Value
Benefit in health care can be conceptualized as having to do with the outcomes that patients experience, which is directly related to the quality of care provided (Fig. 1, numerator) . Quality is improved through efficiency and minimizing complications. Outcomes traditionally include survival and quality of life, but growing attention is being paid to long-term function resulting from treatment, as well as patients' satisfaction with care.
Costs in health care may be thought of both in financial terms as well as the potential harms of treatment. Financial costs can be considered from different perspectives. For instance, a societal or national perspective describes the increasing percentage of health care expenditures as a proportion of gross domestic product, with US health care spending projected to reach nearly 1 in 5 dollars in the coming decades [9] . From the perspective of the middle class family, health insurance premiums have skyrocketed while worker earnings have risen at the same rate as inflation, leaving less money for other monthly expenditures [10, 11] . The other component of health care costs relates to the harms and consequences of treatment. These are not only medical errors and avoidable complications but also wasteful care that leads to additional unnecessary testing and treatment and long-term functional debilitation related to care.
Evaluating Benefit: Quality
To move toward value-based delivery of care, it is helpful to consider the elements of the value equation that physicians can actually control. Quality is near the top of that list. Since the IOM published landmark reports on quality a decade ago [12, 13] , numerous efforts and research have addressed ways Table 1 Waste in US health care, as described in the Institute of Medicine report, "Best care at lower cost: the path to continuously learning health care in America" [3] 
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• All sources-payers, clinicians, patients $75 billion Fig. 1 The elements of the value equation to improve the efficiency of care, the appropriateness of care, and the rate of avoidable complications and errors. Donabedian's model of examining health care quality describes the measurable elements of quality as structure (of health care delivery system), process (the elements of care provided), and outcomes [14] . Here, we address literature in head and neck cancer that examines structure and process as they relate to quality.
Structure
The most studied structural issue in health care and surgery is the relationship between the volume of cases cared for and quality, with higher-volume practitioners and institutions usually able to provide higher-quality care. Gourin has published on the relationship of institutional volume to short-term quality measures in both laryngeal and oropharyngeal cancer surgery using both the Nationwide Inpatient Sample (NIS) as well as the Maryland Health Service Cost Review Commission databases [15] [16] [17] [18] . Chen analyzed data from the National Cancer Database (NCDB) and reported improved long-term survival in both early-and advanced-stage laryngeal cancer at higher-volume institutions [19, 20] . Cheung found similar trends in survival using the Florida cancer registry and inpatient hospital data [21] . Efforts to translate these findings about volume into policy changes have been varied around the globe. In countries like Great Britain, Canada, and Australia, there are explicit efforts to consolidate the care of complex cases into high-volume institutions with the expectation that this will improve quality and reduce costs. These efforts have often included a specific focus on head and neck cancer [22] . In the USA, there are few explicit federal or state policies to drive consolidation of high-risk or complicated cases of head and neck and thyroid cancer, but this kind of regionalization may be happening naturally [23, 24] .
Process
The appropriate processes of care are often specified in guidelines, which are based on expert review of evidence. Guidelines therefore play an increasingly important role in improving the quality and ultimately the value of care. Lewis et al. reviewed whether patients who had received prior treatment for head and neck cancer were given guideline-compliant care before being referred to MD Anderson and found that more than 40 % had not [25•]. We have reported that guidelines impact the delivery of care for thyroid cancer [26] and that guideline familiarity had an impact on the use of surveillance imaging in head and neck cancer [27] . Ultimately, patientcentered guidelines may lead to a greater influence of guidelines on the quality of care [28•].
Coordination of care is an important way to improve the efficiency and quality of care. Many institutions are now housing their head and neck specialists and ancillary support services such as specialized nurses and speech and language pathologists in the same clinic, where patients benefit from better communication between providers. A group in the Netherlands has reported that after implementing their integrated care program and developing indicators to measure its impact [29] , patients have shorter waiting times and better support for nutrition, smoking cessation, and case management issues [30] . Two different groups from Australia have reported on the results of multidisciplinary team (MDT) care. One reported improvement in process-related issues such as waiting times and increased dental and nutrition assessment after the implementation of their MDT, in addition to better adherence to guideline-recommended care such as chemoradiation for advanced disease [31] . Another group demonstrated improved 5-year survival between a head and neck MDT and a general cancer practice at the same institution, which they attributed to appropriate multimodal treatment in the multidisciplinary setting [32] .
Clinical care pathways are algorithms that streamline decision-making to improve the sequence, timing, and completion of steps in the process of care delivery. Groups from the University of Pennsylvania Assessment of postoperative complications remains possibly one of the most prevalent methods of evaluating processes of care in head and neck surgical oncology. However, the way complications are currently reported is neither accurate nor consistent within and across institutions. Significant inconsistencies also exist in the descriptive definition of complications, the grading of their severity, and the definition of the postoperative course. On a national level, the American College of Surgeons' National Surgical Quality Improvement Program (NSQIP) collects high-quality, risk-adjusted, and audited data on postoperative complications and provides feedback to outliers among participating hospitals [36] . Although programs such as NSQIP exist for the very purpose of standardizing data collection efforts, universal adoption has been limited by the labor-intensive, time-consuming, and expensive nature of such data abstraction efforts [37] . NSQIP measures postoperative infections and other general complications related to surgery, which are not specific to head and neck oncology. We have also demonstrated that a reliance on NSQIP data or billing claims data results in underreporting of postoperative complications in oral cavity surgery, impeding efforts to track, study, and improve the quality of care [38] .
Given these challenges, the American Head and Neck Society (AHNS) Quality Committee has recently been tasked with an effort to establish a head and neck surgery specific quality reporting database. This database would be similar in its aims to specialty-specific databases such as the Society of Thoracic Surgeons [39] . The goal of this effort is to provide interested institutions the opportunity to collect, study, and compare performance on perioperative quality measures.
Evaluating Benefit: Outcomes
Good outcomes are the ultimate goal of patient care and are an element that physicians should be empowered to measure and improve. Michael Porter offers a rigorous conceptual model of outcomes that patients care about. Table 2 outlines this model and specifies outcomes relevant to head and neck and thyroid cancer. Porter divides outcomes into three tiers: Tier 1 outcomes are the health status achieved from treatment. Tier 2 outcomes relate to the process of recovery, including time spent recovering and the disutilities of care such as complications and adverse treatment effects. Tier 3 outcomes relate to the sustainability of health, including long-term outcomes and function [1••, 40, 41] .
There has also been a great deal of research on the outcomes of health status and the degree of health and recovery, particularly in the form of quality of life (QoL) instruments. The breadth of QoL instruments in head and neck and thyroid cancer surgery reflects an understanding among providers of the limitations of using survival data as the sole outcome measure. The University of Washing Quality of Life Scale (UW-QoL) is one of the most frequently used, established, and validated QoL instruments [42] . Most importantly, the patient completes the QoL instrument longitudinally throughout the care cycle. The MD Anderson Dysphagia Inventory (MDADI) specifically measures the impact of dysphagia on the QoL in patients receiving treatment for head and neck cancer [43] . This scale, like the UW-QoL, has facilitated measurement of outcomes from the perspective of the patient, shedding light on functional and psychological outcomes that cannot be accurately captured with survival rates alone. One of the ongoing challenges of using QoL instruments is that they require patients to fill out numerical scales, which potentially limits their utility for patients who are not comfortable with numbers [44] .
More recently, there has been work in the development of head and neck specific QoL metrics from the International Classification of Function (ICF) database. The ICF, based on the bio-psycho-social model of health, classifies function the same way the International Classification of Disease classifies diagnoses. The process of developing the ICF Core Sets for head and neck cancer was evidence-based, and a consensus was reached among an eclectic group of experienced representatives from the field [45•] . The end result was the comprehensive ICF Core Set for Head and Neck Cancer (ICF-HNC), with 112 categories ultimately agreed upon that specifically address the functional status of these patients. This has been validated to show it can play a vital role in the multidisciplinary treatment of head and neck cancer, including follow-up and rehabilitation [46] .
Nomograms are receiving growing attention in health care. These are tools that allow individualized prediction of outcomes, which improves both physician and patient decision-making and communication [47••] . In head and neck cancer, nomograms have been developed to predict survival probabilities in major salivary gland malignancies [48, 49] and oral cavity cancer [50, 51] . These nomograms have the added benefit of incorporating variables that influence treatment beyond the classic TNM staging system. Nomograms have also been designed to aid providers in recommending adjuvant therapy to patients [52, 53] . Others have been created to predict the risk of malignancy in a particular thyroid nodule [54, 55] , as well as the risk of developing postoperative complications following surgery for thyroid cancer [56] and oral cavity cancer [57] . Prediction of outcomes and risks in individual patients not only has obvious implications in patient care but also has potential utility in improving quality and value of care by streamlining and optimizing processes of patient care.
Evaluating Costs: Financial
Financial costs in health care are notoriously difficult to measure. Chief among the challenges are the opacity of financial information in health care and the differences between costs, charges, and reimbursement. Costs are what matter in the value equation, but are not the same as the charges leveed for health care, which are yet again different from the amount of money reimbursed or collected [58] . Measuring the costs of care for one individual throughout the entire time-horizon of illness, the truest measure of cost, adds yet another layer of complexity. As difficult as costs are to measure, there are further challenges in trying to decrease costs [59] . Despite these limitations, recent work addresses financial costs in head and neck and thyroid cancer, as well as the cost-effectiveness of services.
Overuse of low-value health care services is the largest driver of waste ( Table 1) . Treatment of cancer poses unique challenges in decreasing the use of low-value care [60] . One successful campaign, at least in terms of opening a dialogue about low-value care and costs, is the Choosing Wisely campaign, which tasks medical societies to come up with lists of overused or unnecessary services [5] . Both the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and the American Society of Clinical Oncology (ASCO) have developed lists; [6••] the American Head and Neck Society (AHNS) has not created a list as of this writing.
Overuse and unnecessary care has been documented in head and neck and thyroid cancer. For instance, there is evidence that the rising incidence of thyroid cancer is due in part to increased detection of small, low-risk, and potentially clinically insignificant tumors [61] . Recent evidence shows that thyroid cancer incidence is correlated with measures of health care access [62••] . After treatment, there is evidence of overuse of radioactive iodine, with nearly one third of patients with tumors less than 1 cm receiving therapy [26, 63] despite guidelines that recommend against such treatment in this group [64] .
Cost-effectiveness analysis, comparative effectiveness analysis, and decision analysis can help determine whether treatments and tests are of low or high value. Work has been done in this arena in the utility of PET/CT for head and neck cancer [65] [66] [67] [68] , surgical versus nonsurgical treatment of laryngeal cancer [69, 70] , and the surgical treatment of thyroid cancers [71] . As we increasingly focus on identifying health care services that are not cost effective, however, we need to be aware of potential unintended consequences such as underuse of necessary care [72•] . Furthermore, we need to understand other types of value that are not easily measured, such as the reassurance and hope that care provides [73] . Finally, we need to be aware of the psychological challenges of trying to get patients and providers to give up low-value services [59] . Controlling health care costs ultimately depends on making changes at the point of care. The MD Anderson Cancer Center is attempting this in a unique way. In collaboration with the Harvard Business School and using head and neck cancer care as a model [74••] , they are working on the methodology of measuring the costs of care over the full cycle of a patient's encounter with the health system. The method is called timedrive activity-based costing [75] and allows accurate calculation of true costs over time in order to identify areas of focus. Such granular methods are a promising way to conceptualize, measure, and ultimately improve the denominator of the value equation.
Evaluating Costs: Harms
The harm that a patient suffers as a result of interacting with the health system decreases the value of the care they receive. While this might be generally acknowledged, there are few efforts to systematically measure meaningful harms in head and neck cancer care or any sector of health care. Conceptually, harms come in several forms, most of which have been previously discussed herein. These include the following: (a) avoidable complications and errors in care, (b) avoidable downstream care resulting from unnecessary low-value diagnostic testing and treatment, (c) psychosocial and financial harms of undergoing treatment, and (d) long-term sequelae of care such as functional outcomes (tier 3 of Porter's hierarchy). To truly improve the value of head and neck cancer care, additional efforts are needed to measure and systematically decrease this component of the value equation denominator.
Conclusions
Health care is a commodity-something we pay for. There is increasing recognition that, as with any other product, we should aim to get the best "bang for the buck" from health care, with the goal ultimately being improved health [76] . The value equation can help us conceptualize how to do this: By focusing on the elements of value that physicians might be able to control, we can direct our research and clinical efforts to make dramatic improvements in the delivery of head and neck cancer care. 
